Drug Trial Radar · NCT06897748
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Apr 12, 2025
Primary completion
Apr 21, 2026
Study completion Apr 21, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate lung function parameters, composite endpoint for exacerbations in chronic obstructive pulmonary disease (COPDCompEx), symptoms and to provide safety information after tozorakimab or placebo administrations in participants with symptomatic chronic obstructive pulmonary disease (COPD) with history of exacerbations and high blood eosinophil counts. Study details include the following: * The maximum duration of the screening/run-in period is 5 weeks. An additional unscheduled visit may be performed prior to randomization to repeat safety assessments as deemed necessary by the investigator. * Eligible patients will enter 12-week treatment (intervention) period with site visits and investigational product (IP) administration every 2 weeks. * Participants who complete a treatment period, and have not been prematurely discontinued from IP, will enter a 10-week post-intervention follow-up period. * The study duration will be 27 weeks at maximum for each participant.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
PlaceboDrug
Placebo administered subcutaneously, equivalent volume to tozorakimab throughout the study
TozorakimabDrug
Administered subcutaneously tozorakimab and placebo throughout the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Pre-bronchodilator Forced Expiratory Volume in 1 Second (Pre-BD FEV1) as Measured in ClinicTime frame: Baseline through Week 12
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Aramil, Russia
Research Site
Izhevsk, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Omsk, Russia
Research Site
Penza, Russia
Research Site
Perm, Russia
Research Site
Saint Petersburg, Russia
Research Site
Saratov, Russia
Research Site
Ulyanovsk, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.